Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture

Biomaterials

Volumn 33, Issue 3, 2012, Pages 907-915

  Leeper, Alexander D ^a   Farrell, Joanne ^b   Williams, Linda J ^c   Thomas, Jeremy S ^a   Michael Dixon, J ^a   Wedden, Sarah E ^b   Harrison, David J ^a   Katz, Elad ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Breast cancer; Computer assisted image analysis; ECM; Estrogen receptor; Organotypic cultures; Tamoxifen

Indexed keywords

BREAST CANCER; COMPUTER ASSISTED; ESTROGEN RECEPTOR; ORGANOTYPIC CULTURE; TAMOXIFEN;

CELL CULTURE; CELL DEATH; COLLAGEN; DISEASES; IMAGE ANALYSIS; MILITARY ELECTRONIC COUNTERMEASURES; OPTICAL PROJECTORS; POISSON DISTRIBUTION; REGRESSION ANALYSIS; THREE DIMENSIONAL; TOMOGRAPHY; TUMORS;

MEDICAL IMAGING;

CASPASE 3; COLLAGEN TYPE 1; ESTROGEN RECEPTOR; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SIZE; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OPTICAL TOMOGRAPHY; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE CULTURE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; COLLAGEN; FEMALE; HUMANS; TAMOXIFEN; TISSUE CULTURE TECHNIQUES;

EID: 81155150349     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.028     Document Type: Article

References (45)

1. Brown S.B., Mallon E.A., Edwards J., Campbell F.M., McGlynn L.M., Elsberger B., et al. Is the biology of breast cancer changing? a study of hormone receptor status 1984-1986 and 1996-1997. Br J Cancer 2009, 100(5):807-810.
2. NICE Clinical guideline 80 early and locally advanced breast cancer 2009.
3. Miller W.R., Dixon J.M., Macfarlane L., Cameron D., Anderson T.J. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003, 39(4):462-468.
4. Colleoni M., Giobbie-Hurder A. Benefits and adverse effects of endocrine therapy. Ann Oncol 2010, 21(Suppl. 7):vii107-vii111.
5. Hackshaw A., Baum M., Fornander T., Nordenskjold B., Nicolucci A., Monson K., et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009, 101(5):341-349.
6. Young O.E., Renshaw L., Macaskill E.J., White S., Faratian D., Thomas J.S., et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 2008, 44(3):391-399.
7. Lawson A.H., Riches A.C., Weaver J.P. Human bladder tumors in organ culture. J Urol 1986, 135(5):1061-1065.
8. Nomura Y., Tashiro H., Hisamatsu K. Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar. J Natl Cancer Inst 1990, 82(13):1146-1149.
9. Nakamura J., Imai E., Yoshihama M., Sasano H., Kubota T. Histoculture drug response assay, a possible examination system for predicting the antitumor effect of aromatase inhibitors in patients with breast cancer. Anticancer Res 1998, 18(1A):125-128.
10. Matsuoka H., Nakamura Y., Ueo H., Sugimachi K., Tomoda H., Saito T., et al. Interrelationship between estradiol and tamoxifen responses for clinical breast carcinoma cells cultured on contact-sensitive plates. Jpn J Cancer Res 1994, 85(6):619-625.
11. Cottu P.H., Assayag F., De Plater L., Elbaz C., Karboul N., Marangoni E., et al. Establishment and characterization of human luminal breast cancer xenografts. San Antonio Breast Cancer Symposium; 2010; San Antonio 2010, p. S6-S7.
12. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527.
13. Harrell J.C., Dye W.W., Allred D.C., Jedlicka P., Spoelstra N.S., Sartorius C.A., et al. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 2006, 66(18):9308-9315.
14. Osborne C.K., Hobbs K., Clark G.M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985, 45(2):584-590.
15. Taylor K.J., Sims A.H., Liang L., Faratian D., Muir M., Walker G., et al. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res 2010, 12(3):R39.
16. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7(9):659-672.
17. Katz E., Streuli C.H. The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol 2007, 39(4):715-726.
18. Katz E., Lareef M.H., Rassa J.C., Grande S.M., King L.B., Russo J., et al. MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture. J Exp Med 2005, 201(3):431-439.
19. Eritja N., Llobet D., Domingo M., Santacana M., Yeramian A., Matias-Guiu X., et al. A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol 2010, 176(6):2722-2731.
20. Xu R., Boudreau A., Bissell M.J. Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 2009, 28(1-2):167-176.
21. Lu C., Li X.Y., Hu Y., Rowe R.G., Weiss S.J. MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood 2010, 115(2):221-229.
22. Harma V., Virtanen J., Makela R., Happonen A., Mpindi J.P., Knuuttila M., et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5(5):e10431.
23. Krause S., Maffini M.V., Soto A.M., Sonnenschein C. A novel 3D in vitro culture model to study stromal-epithelial interactions in the mammary gland. Tissue Eng Part C Methods 2008, 14(3):261-271.
24. Dhimolea E., Maffini M.V., Soto A.M., Sonnenschein C. The role of collagen reorganization on mammary epithelial morphogenesis in a 3D culture model. Biomaterials 2010, 31(13):3622-3630.
25. Katz E., Dubois-Marshall S., Sims A.H., Faratian D., Li J., Smith E.S., et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer 2010, 103(3):401-410.
26. Katz E., Verleyen W., Blackmore C.G., Edward M., Smith V.A., Harrison D.J. An analytical approach differentiates between individual and collective cancer invasion. Anal Cell Pathol 2011, 34(1):35-48.
27. Leeper A.D., Farrell J., Dixon J.M., Wedden S.E., Harrison D.J., Katz E. Long-term culture of human breast cancer specimens and their analysis using optical projection tomography. J Vis Exp 2011, (1):3085. 10.3791/3085.
28. Lloyd M.C., Allam-Nandyala P., Purohit C.N., Burke N., Coppola D., Bui M.M. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: how reliable is it?. J Pathol Inform 2010, 1:29.
29. Sharpe J., Ahlgren U., Perry P., Hill B., Ross A., Hecksher-Sorensen J., et al. Optical projection tomography as a tool for 3D microscopy and gene expression studies. Science 2002, 296(5567):541-545.
30. Katz E., Dubois-Marshall S., Sims A.H., Gautier P., Caldwell H., Meehan R.R., et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS One 2011, 6(2):e17083.
31. Dabrosin C. Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle. J Endocrinol 2005, 187(1):103-108.
32. Kisanga E.R., Gjerde J., Guerrieri-Gonzaga A., Pigatto F., Pesci-Feltri A., Robertson C., et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004, 10(7):2336-2343.
33. Alanentalo T., Asayesh A., Morrison H., Loren C.E., Holmberg D., Sharpe J., et al. Tomographic molecular imaging and 3D quantification within adult mouse organs. Nat Methods 2007, 4(1):31-33.
34. Estrada C.R., Salanga M., Bielenberg D.R., Harrell W.B., Zurakowski D., Zhu X., et al. Behavioral profiling of human transitional cell carcinoma ex vivo. Cancer Res 2006, 66(6):3078-3086.
35. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., Griffith C., et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005, 11(2 Pt. 2):951s-958s.
36. Kuperwasser C. The tumor stromal microenvironment as modulator of malignant behavior. J Mammary Gland Biol Neoplasia 2010, 15(4):377-379.
37. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9(9):665-674.
38. Cameron D.A., Keen J.C., Dixon J.M., Bellamy C., Hanby A., Anderson T.J., et al. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur J Cancer 2000, 36(7):845-851.
39. Dowsett M., A'Hern R., Salter J., Zabaglo L., Smith I.E. Who would have thought a single Ki67 measurement would predict long-term outcome?. Breast Cancer Res 2009, 11(Suppl. 3):S15.
40. Harry V.N., Semple S.I., Parkin D.E., Gilbert F.J. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010, 11(1):92-102.
41. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25(28):4414-4422.
42. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19(18):3808-3816.
43. Ahn S.H., Son B.H., Kim S.W., Kim S.I., Jeong J., Ko S.S., et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 2007, 25(17):2360-2368.
44. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25(33):5287-5312.
45. Symmans W.F., Hatzis C., Sotiriou C., Andre F., Peintinger F., Regitnig P., et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010, 28(27):4111-4119.